Targeted <b>α</b>-Emitter Therapy with <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial-Reference-Cited by-同舟云学术

Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial

Published:2022-01-06 Issue:9 Volume:63 Page:1326-1333
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Delpassand Ebrahim S.,Tworowska Izabela,Esfandiari Rouzbeh,Torgue Julien,Hurt Jason,Shafie Afshin,Núñez Rodolfo

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference21 articles.

1. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

2. Somatostatin Receptor Antagonists for Imaging and Therapy

3. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future;Stueven;Int J Mol Sci.,2019

4. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018

5. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors;Das;Expert Rev Gastroenterol Hepatol.,2019

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies;Current Problems in Cancer;2024-10

2. Efficiency and Safety of Targeted Alpha Therapy in Metastatic Neuroendocrine Tumors;Clinical Nuclear Medicine;2024-08-22

3. May the Nuclear Medicine be with you! Neuroendocrine tumours and the return of nuclear medicine;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-19

4. Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles;Journal of Labelled Compounds and Radiopharmaceuticals;2024-08-15

5. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy;Pharmaceuticals;2024-08-05